XOMA Royalty Corporation, based in Emeryville, California, recently declared their quarterly preferred stock dividends for holders of XOMA’s Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) are set to receive a cash dividend of $0.53906 per share. Similarly, holders of depositary shares representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive a cash dividend of $0.52344 per depositary share. The dividends are scheduled to be paid around October 15, 2024, to shareholders of record as of October 3, 2024.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator, assisting biotech companies in advancing human health initiatives. The company acquires potential future economics associated with pre-commercial therapeutic candidates and commercial assets licensed to pharmaceutical or biotechnology firms. This arrangement allows the original sellers to receive non-dilutive, non-recourse funding for furthering their internal drug candidates or general corporate purposes. With over 70 assets in its portfolio, XOMA Royalty Corporation continues to grow its presence in the industry. The company’s milestone and royalty portfolio include commercial assets like VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). It’s important to note that all other assets in the portfolio are investigational compounds, with efficacy and safety yet to be established, and there’s no guarantee of commercial availability.
For more information about XOMA Royalty Corporation and its diverse portfolio, interested individuals can visit www.xoma.com or follow the company on LinkedIn. If you have any investor-related inquiries, you can reach out to Juliane Snowden at +1 646-438-9754 or juliane.snowden@xoma.com. Media inquiries can be directed to Kathy Vincent at KV Consulting & Management by calling +1 310-403-8951 or emailing kathy@kathyvincent.com.